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Background: Based on binding of invariant chain (Ii) to major histocompatibility complex (MHC) class II molecules
to form complexes, Ii-segment hybrids, Ii-key structure linking an epitope, or Ii class II-associated invariant chain
peptide (CLIP) replaced with an epitope were used to increase immune response. It is currently unknown whether
the Ii-segment cytosolic and transmembrane domains bind to the MHC non-peptide binding region (PBR) and
consequently influence immune response. To investigate the potential role of Ii-segments in the immune response
via MHC II/peptide complexes, a few hybrids containing Ii-segments and a multiepitope (F306) from Newcastle
disease virus fusion protein (F) were constructed, and their binding effects on MHC II molecules and specific
antibody production were compared using confocal microscopy, immunoprecipitation, western blotting and animal
experiments.
Results: One of the Ii-segment/F306 hybrids, containing ND (Asn–Asp) outside the F306 in the Ii-key structure
(Ii-key/F306/ND), neither co-localized with MHC II molecules on plasma membrane nor bound to MHC II molecules
to form complexes. However, stimulation of mice with the structure produced 4-fold higher antibody titers
compared with F306 alone. The two other Ii-segment/F306 hybrids, in which the transmembrane and cytosolic
domains of Ii were linked to this structure (Cyt/TM/Ii-key/F306/ND), partially co-localized on plasma membrane with
MHC class II molecules and weakly bound MHC II molecules to form complexes. They induced mice to produce
approximately 9-fold higher antibody titers compared with F306 alone. Furthermore, an Ii/F306 hybrid (F306
substituting CLIP) co-localized well with MHC II molecules on the membrane to form complexes, although it
increased antibody titer about 3-fold relative to F306 alone.
Conclusions: These results suggest that Ii-segments improve specific immune response by binding to the non-PBR
on MHC class II molecules and enabling membrane co-localization with MHC II molecules, resulting in the
formation of relatively stable MHC II/peptide complexes on the plasma membrane, and signal transduction.
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Major histocompatibility complex (MHC) class II mole-
cules play an important role in antigen presentation,
with the binding antigen peptide as a key step in initiat-
ing the specific immune response. In this process, the
invariant chain (Ii) acts as a chaperone for the correct
folding and the functional stability of MHC II molecules
[1]. Ii is described initially as a nonpolymorphic type II
integral membrane protein [2], binding MHC II α and β
chains to form αβ/Ii complexes. These αβ/Ii complexes
have been identified on B cell and dendritic cell surfaces
[3-5]. In epithelial cells, the endocytosis of αβ/Ii com-
plexes is highly dependent on the Ii di-leucine motif
[6,7]. Ii limits HLA-DR egress from the endoplasmic
reticulum [8] and prevents loading of self-peptide
[2,9,10]. In immature lysosomes, Ii is proteolyzed [11],
and its class II-associated invariant chain peptide (CLIP)
is replaced by an antigenic peptide [12]. In B cells, the
major pathway of Ii-associated MHC class II molecules
involves direct access to the endolysosomal compart-
ments for peptide loading [13].
The mouse Ii isoform Ii31 consists of the cytosolic
and transmembrane domains and luminal domain that
contains CLIP and the trimerization region [14]. The
cytosolic domain (Cyt) contains an endosome-targeting
signal that is essential for Ii targeting to the endosomal
compartment, via the plasma membrane alone or the
MHC class II complex [15,16]. The transmembrane do-
main (TM) plays a key role in the formation of Ii tri-
mers [17] and in the degradation of Ii [18], thereby
influencing MHC class II molecular functions, including
complex formation and antigen presentation [19]. The
CLIP binds MHC class II peptide binding region (PBR)
and interacts with class II molecules [10,20]. The tri-
merization region is involved in the generation of this
endosomal localization signal [17].
A method to increase antigen-specific stimulation of
T-helper cells entails the use of the Ii hybrids, in which a
four-amino-acid sequence (LRMK) is linked to T-helper
epitopes [21-23], or the Ii peptide (CLIP) region is
replaced with the various epitopes [24,25]. Animal mod-
els illustrate the efficiency of Ii hybrid methodology in
using melanoma peptides [21,26], subvirion influenza A
(H5N1) HA [22], human papilloma virus 16 E7(8–22)
[23], Listeria Th [24] and hepatitis C virus [25] epitopes.
The mechanistic hypothesis states that the Ii -key binds
initially to an allosteric site just outside the MHC class
II binding groove at the cell surface [26,27]. This induces
a conformational change in the trough, facilitating anti-
genic epitope charging [22,28], and a concomitant in-
crease in the potency of antigen presentation compared
with the unmodified class II epitope [29,30]. As vector,
Ii-key and Ii can enhance the interferon (IFN)γ and
interleukin (IL)-4 or IL-2 responses in enzyme-linkedimmunosorbent spot assay [21,24], epitope-specific CD4+
T cell activation [23], or specific antibody production
[25]. The Ii-hybrids can also function in desensitizing al-
lergy [31] and inducing antigen-specific tolerance and
ameliorating arthritis [32]. All these findings indicate po-
tential clinical use of such allosteric site-directed, Ii-
segment drugs [27].
The Ii-key lies outside the N-terminal of CLIP and
plays an important role in CLIP loading in the MHC II
PBR. Hypothetically, the DN (Asn–Asp) segment, lying
just outside the C-terminal of CLIP (Figure 1A), would
promote epitope association with the PBR, in a similar
manner to the Ii-key. Furthermore, some of the Ii-
segments have a potential immune function [19,20,29].
The cytosolic and transmembrane domains are involved
in localization and binding to MHC class II molecules,
with the former containing an endosome-targeting signal
[15,16]. It is unclear whether the Ii-segments in the
hybrids are able to induce a conformational change that
enables antigenic peptide charging, stabilizing the MHC
II/peptide complexes and enhancing specific immune
responses, when Ii hybrid binds MHC II molecules to
form complexes, in which the epitope binds to the PBR
and the other segments to the non-PBR. Therefore, we
constructed such hybrids to determine their binding ef-
fect with MHC II molecules, and antibody production.
Results
Construction and identification of the Ii-segment epitope
hybrids
We amplified Ii-segments from the mouse Ii cDNA gen-
erated in our previous work [33], and then constructed
the hybrids containing fusion genes of Ii-segments and a
multiepitope containing three potential epitopes, named
F306 [34], from Newcastle disease virus fusion protein
(F). A schematic diagram in Figure 1A shows the struc-
tures of these hybrids. After identification with electro-
phoresis and sequencing, they (Ii, Ii/F306, F306, Ii-key/
F306, Ii-key/F306/DN, Cyt/Ii-Key/F306/, Cyt/TM/Ii-
Key/F306/DN) (Figure 1B) were inserted into the
eukaryotic expression vectors pmCherry-C1 for transfec-
tion or the prokaryotic expression vectors to construct
pGEX-4 T-1 for expression in Escherichia coli for
immunization (GST- Ii/F306, GST-F306, GST-Ii-key/
F306, GST-Ii-key/F306/DN, GST-Cyt/TM/Ii-Key/F306,
and GST-Cyt/TM/Ii-Key/F306/DN). pET-32a-F306 was
constructed in order to purify F306 multiepitope which
in turn was used as a coating antigen for ELISA. These
expressed proteins were purified and identified
(Figure 1C). Additionally, mouse H2-Aa, H2-Ab and
full-length Ii genes (Figure 1B) were also amplified and
inserted in eukaryotic expression vectors (Table 1) for
transfection, immunoprecipitation or western blotting,
respectively.
Figure 1 Constructed, expressed and purified hybrids
containing Ii-segments and antigen peptides. A. Schematic
diagram of hybrids containing Ii-segments and antigen peptides. a.
Full-length Ii consists of cytosolic domain (Cyt), transmembrane
domain (TM) and luminal domain, which includes an Ii-key sequence
(L1), CLIP (L2), DN sequence (L3) and trimerization region (L4). b.
Components of reconstructed hybrids. These hybrids contain
different Ii-segments and a multiepitope, F306. c. Structure of F306.
F306 consisted of three potential epitopes in fusion protein of
Newcastle disease virus and had a predicted molecular weight of
11.2 kDa. B. PCR-amplified gene and hybrid DNA segment products:
mouse H2-Aa, H2-Ab, full-length Ii, Ii/F306, multi-epitope F306 and
the hybrids, Ii-key/F306, Ii-key/F306/DN, Cyt/TM/Ii-Key/F306/ and Cyt/
TM/Ii-Key/F306/DN. C. Expressed and purified products. PCR-
amplified F306 and hybrid DNA were cloned into prokaryotic
expression vectors, pGEX-4 T-1 or pET-32a, and expressed. Purified
products: GST-Ii/F306, GST-F306, GST-Ii-key/F306, GST-Ii-key/F306/DN,
GST-Cyt/TM/Ii-Key/F306, and GST-Cyt/TM/Ii-Key/F306/DN for
immunization and His-F306 for coating in ELISA.
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Complexes involving MHC II α, β and Ii (αβ/Ii) at
the cell surface [3-7] resulted from binding with
hybrids containing different Ii-segments. We carried
out immunoprecipitation and western blotting to es-
tablish how Ii segments in the hybrids bound to
MHC class II molecules. The results indicated that
the full-length Ii and the Ii/F306 hybrid bound MHC
II β chain strongly (Figure 2, lanes 1 and 2) (α chain
data not presented). Another hybrid containing the
transmembrane and cytosolic domains (Cyt/TM/Ii-key/
F306/DN) also bound MHC class II molecules (Figure 2,
lane 3), and the hybrids containing cytosolic domain
(Cyt/Ii-key/F306/DN) or containing only Ii-key and DN
(Ii-key/F306/DN) (Figure 2, lanes 4 and 5) failed to
bind MHC class II molecules. These results indicated
that besides the trimerization region, the other seg-
ments, such as the cytosolic and transmembrane
domains together (Cyt/TM), had a role in binding to
MHC class II molecules. Because Ii or Ii hybrids bind
to the MHC II molecule, Ii CLIP region or the epi-
tope F306 in the Ii hybrids loaded in the PBR, Ii
functional segments might bind non-PBRs of MHC II
molecules.
Some Ii segments co-localized with MHC class II
molecules on the plasma membrane
To determine where in the cells the segments bind
MHC class II α or β chains, we cotransfected COS7 cells
with these segments or hybrids as well as H2-Aa or H2-
Ab. MHC II α or β chains (Figure 3a–f, left), full-length
Ii (Figure 3a, middle) and Cyt/TM/Ii-key/CLIP(F306)/
ND (Figure 3d and f, middle) were expressed on the
plasma membrane in the transfected COS7 cells, but the
Ii-segments, Cyt/Ii-key/CLIP/DN (Figure 3c middle)
were not expressed. The complete co-localization of full-
length Ii and Ii/F306 hybrid with MHC II α or β chain
on the plasma membrane resulted in the appearance of
a uniform range or yellow-orange accumulation in the
merged images (Figure 3a and b, merged). It depended
on molecular integrity, because full-length Ii and Ii/F306
hybrid contained the cytosolic and transmembrane
domains for membrane localization and the trimerization
region for polymerization. In the presence of cytosolic
and transmembrane domains, however, the Ii-segments
(Cyt/TM/Ii-key/CLIP/ND) and Ii-segment/epitope hy-
brid (Cyt/TM/Ii-key/F306/ND) resulted in partial co-
localization with MHC II α or β chain, which was
consistent with the imaging results observed in Figure 3d
and f. All the other Ii-segments and hybrids, which
lacked the transmembrane domain and trimerization
region, such as Cyt/Ii-key/CLIP/ND, Ii-key, Ii-key/CLIP,
Ii-key/CLIP/DN (images not presented) and Cyt/Ii-key/
Table 1 Primers, cloned Ii-segments and reconstructed vectors in this study
No. Primer sequences (5´-´) Reconstructed vectors
1 Forward: 5'gaagatctaatgccgtgcagcagagc3' pEGFP-N1-H2-Aa (1)
Reverse: 5'gcgtcgacactaaaggccctggg3'
2 Forward: 5'gaagatcttatggctctgcagatcccc3' pEGFP-N1-H2-Ab (1)
Reverse: 5'gcgtcgacatcgcaggagccct3'
3 Forward: 5'cccgaattcacatggctctgcagatccc3' pCMV-Myc-H2-Ab (2)
Reverse: 5'ggaagatctatcactgcaggagccct3'
4 Forward: 5'cccgaattctatggctctgcagatcccc3' pmCherry-C1-Ii (1)
Reverse: 5'gcgtcgactcacagggtgacttga3' pEGFP-C1-Ii (3)
5 Forward1: 5'ccgctcgagacatgcaacgcgacct3' pmCherry-C1-Ii/F306 (1)





6 Forward: 5'gaattcgatgcttcgcatgaagcttcc3' pmCherry-C1-Ii-Key/CLIP/DN (1)
Reverse: 5'gtcgacctagttatccatgaacat3'
7 Forward: 5'ccggaattcgatgcaacgc3' pmCherry-C1-Cyt/Ii-Key/CLIP/DN (1)
Reverse: 5'gtcgacctagttatccatggacat3'
8 Forward: 5'gaattcgatgcttcgcatgaagcttcc3' pmCherry-C1-Cyt/TM/Ii-Key/CLIP/DN (1)
Reverse: 5'gtcgacctagttatccatggacat3'
9 Forward: 5'ccgctcgagacatgcttcgcatgaag3' pmCherry-C1-Ii-key/F306/DN (1)
Reverse: 5'cgggatcctcagttatcataaatacc3' pEGFP-C1-Ii-key/F306/DN 3)
10 Forward: 5'ccggaattcgatgcaacgc3' pmCherry-C1-Cyt/Ii-Key/F306/DN (1)
Reverse: 5'ccgctcgagctagttatccat3' pEGFP-C1-Cyt/Ii-Key/F306/DN 3)
11 Forward: 5'ccgctcgagatatgcaacgcgacctca3' pmCherry-C1-Cyt/TM/Ii-Key/F306/DN (1)
Reverse: 5'cggcatcctcagttatcataaatacc3'
12 Forward: 5'ccggaattcatgctcccaaatatg3' pEGFP-C1-Cyt/TM/Ii-Key/F306/DN (3)
Reverse: 5'ccgctcgagtcaataaataccagg3'
13 Forward: 5'ccggaattcatgcttcgcatgaagctc3' PGEX-4T-1-Ii-key/F306 (4)
Reverse: 5'ccgctcgagtcaataaataccaggag3'
14 Forward: 5'ccggaattcatgcttcgcatgaagctc3' PGEX-4T-1-Ii-key/F306/DN (4)
Reverse: 5'ccgctcgagtcaataaataccagg3'
15 Forward: 5'cgggatccatgcaacgcgacct3' PGEX-4T-1-Cyt/TM/Ii-Key/F306 (4)
Reverse: 5'ccgctcgagtcaataaataccag3'
16 Forward: 5'cgggatccatgcaacgcgacct3' PGEX-4T-1-Cyt/TM/Ii-Key/F306/DN (4)
Reverse 5'ccgctcgagtcagttatcaccagga3'
17 Forward: 5'cgggatccatgcaacgcgacct3' PGEX-4T-1-Ii/F306 (4)
Reverse: 5'cgggatcctcacagggtgacttgaccc3'
18 Forward: 5'ccggaattcatgctcccaaatatgcctaag3' PGEX-4T-1-F306 (4)
Reverse: 5'ccgctcgagtcaataaataccaggagacataggg3' pET-32a-F306 (5)
The design of all the primers was based on the reported cDNA sequences: mouse Ii from GenBank ID: NM_010545, mouse H2-Aa from GenBank ID: NM_010378,
mouse H2-Ab from GenBank ID: AY_452202 and NDV F gene from GenBank ID: AY_508514. The reconstructed vectors were used for CLSM (1), for IP (2), for WB
(3), for expression as immunization antigens (4)or for expression as coating antigen in ELISA (5).
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lanes 4 and 5), even if they were localized in the cyto-
sol (Cyt/Ii-key/CLIP/ND) (Figure 3c, middle) or cell
membrane (Cyt/Ii-key/F306/ND) (Figure 3e, middle).The differences in the merged images (Figure 3a, b, d
and f, merged) hypothetically resulted from the degree
of tight binding of the hybrids with MHC class II
molecules.
Figure 2 Binding of Ii, Ii-segments, Ii-segments/F306 or Ii/F306
hybrids to MHC II β chain. Mouse H2-Ab/Myc was cotransfected
with mouse Ii gene Ii/GFP (1), Ii/F306 hybrids (2), Cyt/TM/Ii-key/F306/
DN/GFP (3), Cyt/Ii-key/F306/DN/GFP (4) or Ii-key/F306/DN/GFP (5) in
COS7 cells. After 36 h, the cells were lysed and the antibody against
Myc was added for immunoprecipitation. Subsequently, the immune
complexes (lanes 1–5), cell lysates transfected with only H2-Ab/Myc
(lane 6) and control cells without transfection (lane 7) were
separated by SDS-PAGE, immunoblotted and detected with
antibodies against GFP (WB1) or Myc (WB2). These fusion proteins
had molecular weights of 51.0 kDa (Ii/GFP), 58.9 kDa (Ii/F306/GFP),
45.7 kDa (Cyt/TM/Ii-key/F306/DN/GFP), 31 kDa (Cyt/Ii-key/F306/DN/
GFP) and 27.7 kDa (Ii-key/F306/DN/GFP), in which GFP had a
molecular weight of 27 kDa.
Chen et al. BMC Immunology 2012, 13:55 Page 5 of 9
http://www.biomedcentral.com/1471-2172/13/55All the Ii-segments increased immune response
To establish whether Ii-segments, which bound and co-
localized with MHC class II molecules, improved im-
mune response, we immunized mice with these hybrids,
including F306 alone, and measured the specific anti-
body levels. As illustrated in Figure 4, we detected an
antibody titer of 1.62 ± 0.53 × 104 using ELISA in mice
immunized with F306 alone. The Ii-key/F306 or Ii-key/
F306/DN hybrids induced antibody titers approximately
2-fold (3.12 ± 1.15 × 104) or 4-fold (6.30 ± 1.26 × 104)
higher, respectively, compared with F306 alone. More-
over, the hybrids containing the cytosolic and transmem-
brane domains, Cyt/TM/Ii-key/F306 or Cyt/TM/Ii-key/
F306/DN, elicited up to approximately 9-fold higher
antibody titer (12.40 ± 1.11 × 104or 13.03 ± 1.56 × 104)
than F306 alone. However, the Ii/F306 hybrid induced
an antibody titer approximately 3-fold (4.52 ± 1.22 × 104)
higher compared with F306 alone. These results sug-
gested that, except for the trimerization region, the
tested Ii-segments played a role in boosting the immune
response in different ways, affecting the non-PBR of
MHC class II molecules and immune cells.Conclusions
We demonstrated by immunoprecipitation and western
blotting that Ii segment cytosolic and transmembrane
domains bound to MHC class II molecules, and by con-
focal microscopy that they co-localized on the plasma
membrane with MHC class II molecules in transfected
cells. Although the amino acid sequences lying outside the
N and C terminal segments of CLIP, Ii-key and DN, nei-
ther bound to nor co-localized with MHC class II mole-
cules, the both segments made the epitope in the hybrids
concomitantly more stable when associated with a PBR .
Together with the cytosolic and transmembrane
domains, these amino acid sequences associate with the
non-PBR of MHC class II molecules to form complexes,
hybrid/MHC II, which might be better for presenting
epitopes to immune cells, improving specific antibody
production.
Discussion
Ii-key and DN facilitate epitope loading in MHC II PBR
The conformation of the MHC class II molecules plays
an important role in peptide association [35-41]. Binding
of peptide to MHC class II molecules involves several
conformational changes, including a transient “peptide-
receptive” conformation [41-43]. The efficient generation
of long-lived peptide/class II complexes involves two
stages: initial conditioning of MHC class II molecules in
an acidic environment, forming a floppy MHC that
increases the ability of class II molecules to enter a com-
pact conformation, upon binding to specific peptides
[35]; whereas the mature peptide-loaded MHC class II
molecules appear as compact heterodimers [44]. Ii-key
and DN lie just outside N and C termini of the CLIP re-
gion, respectively. Ii-key facilitates epitope loading of
MHC class II molecules at the cell surface [26,27]. DN,
two relatively conserved residues and hypothetically
similar to Ii-key, help CLIP bind to the MHC class II
PBR, enabling effective and stable epitope (F306) loading
of the PBR. Furthermore, the MHC class II molecules
exist in at least two different conformations with respect
to their peptide-binding ability; one more receptive to
binding than the other [45]. The peptide may configure
a class II MHC structure [35,36], resulting in a compact
conformation facilitating charging of epitopes [28]. Ii-
key and DN possibly enhance the loading stability of Ii-
key/F306 or Ii-key/F306/DN with MHC class II PBR, to
induce a conformational change in the trough and facili-
tate effective epitope charging [28] and generation of
long-lived peptide/class II complexes [35], affecting T
cell secretion of IFN and increased humoral immune re-
sponse [28]. However, the affinity between Ii-key and
DN, and MHC class II molecule is not sufficient to form
complexes in cotransfected cells or immunoprecipitation
(Figure 2).
Figure 3 Interaction between MHC class II molecule and Ii-
segments or hybrids in co-transfected COS7 cells. Cells were
transiently co-transfected with the reconstructed pEGFP-N1-H2-Aa or
pEGFP-N1-H2-Ab expressing gene of fusion protein (GFP/MHC class II
alpha or beta chain) and the reconstructed pmCherry-C1s expressing
genes of fusion protein (RFP/Ii hybrids or RFP/Ii-segments),
respectively. After 24 h, the cells were observed using CLSM
and× 60 oil objective. a) Mouse Ii and MHC II alpha or beta chain. b)
Mouse MHC II alpha or beta chain and Ii/F306 hybrid. Both
molecules co-localized with MHC II molecules to plasma membrane
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PBR improves epitope loading in MHC class II PBR
The Ii and the Ii-segment/F306 hybrids bind MHC class
II α or β chains as complexes on the plasma membrane
(Figures 2 and 3), based on their trimerization region.
The Cyt/TM/Ii-key/F306(CLIP)/DN lacks the trimeriza-
tion region, although it also binds MHC class II mole-
cules to form visible complexes (Figures 2 and 3). The
transmembrane domain has a role in the formation ofvisualized in the merged images represented in orange. c) Mouse
MHC II alpha or beta chain and Cyt/Ii-key/CLIP/DN. d) Mouse MHC II
alpha or beta chain and Cyt/Ii-key/F306/DN. Both Ii-segments
localized in cytosol or to plasma membrane and appeared with
absent co-localization with MHC II molecules as visualized in the
merged image. e) Mouse MHC II alpha or beta chain and Cyt/TM/Ii-
key/CLIP/DN hybrids. f) Mouse MHC II alpha or beta chain and
hybrids Cyt/TM/Ii-key/F306/DN. Both hybrids localized on plasma
membrane, but appeared with relative weak interaction with MHC II
molecules visualized in the merged image represented in dispersive
yellow-orange, respectively.αβ/Ii trimers [17]: along with Ii-key and DN, it is the
third factor for binding to MHC class II molecules and
maintaining stability of epitope/MHC II complexes.
However, this domain also co-localizes to the membrane
with MHC class II molecules. The MHC class II mole-
cules require localization on the membrane rafts for sig-
nal transduction [46]. A preferential localization ofFigure 4 Effect of the Ii-segments on F306-specific antibody
responses in the different hybrid immunized Balb/c mice. Balb/c
mice were injected i.p with antigen: F306, Ii hybrids (GST-Ii-key/F306,
GST-Ii-key/F306/DN, GST-Cyt/TM/Ii-key/F306, GST-Cyt/TM/Ii-key/F306/
DN or GST-Ii/F306) at week 0, and boosted at weeks 2 and 3 with
the identical antigen or hybrids. The mice were bled at weeks 4 for
the evaluation of F306-specific serum antibodies by ELISA, in which
His-F306 was used as the coating antigen. Each bar represents
mean± SD values obtained from individual mice (5 mice per group).
These experiments were performed three times with similar results.
The antibody titers between all of two groups had significant
differences (P < 0.01).
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brane results in optimal antigen presentation [47-49]. In
addition, the cytosolic domain contains an endosome-
targeting signal for immune regulation [15,16]. The
binding of the non-PBR via Ii functional segments, co-
localization with MHC II on the membrane, and signal
transduction are sufficient for stable complex formation,
antigen presentation and initial immune response.
Ii-segments are a potential immune carrier
The Ii/F306 hybrid bound MHC class II molecules
strongly to form complexes on the plasma membrane
(Figure 3). It stimulated an intermediate immune re-
sponse, which was lower than that of other hybrids con-
taining cytosolic and transmembrane domains
(Figure 3). Under normal conditions, the MHCII/Ii com-
plex is directed to endosomes [50,51] and then to imma-
ture lysosomes, where the Ii is proteolyzed [12], and the
CLIP is replaced by an antigenic peptide [13]. The Ii/
F306 hybrid contains a trimerization region at its C
terminus, which enables the Ii hybrid/MHC II molecule
to form stable complexes. However, tight binding be-
tween MHC class II molecules and Ii/F306 hybrid might
prevent Ii/F306 hybrid release to bind other MHC class
II molecules and activate other immune cells. In other
words, the trimerization region disrupts contact with
receptors at other cell surfaces, which is necessary for
initiation of the immune response when MHC class II
molecules present antigenic peptide. In contrast to Ii/
F306 hybrid, the other Ii-segment/epitope hybrids such
as Cyt/TM/Ii-key/F306/DN bind MHC class II mole-
cules on the plasma membrane weakly, which is suffi-
cient to form relatively stable complexes to induce an
immune response, but also for its disassembly to bind
and activate more immune cells. In brief, these Ii-
segments may be used as a carrier to promote specific
immune responses.
Methods
Cloning and construction of the hybrids
We cloned various Ii functional segments from mouse Ii
cDNA using PCR and constructed the Ii-segment/F306
hybrids (Figure 1) with a series of primers (Table 1). We
also cloned mouse H2-Aa and H2-Ab genes with the pri-
mers (Table 1). An Ii/F306 hybrid, in which the CLIP re-
gion was replaced by F306, was constructed by overlap
extension PCR. The constructed Ii-segments or hybrids
were then inserted into eukaryotic vector pmCherry-C1
or pEGFP-C1 (Table 1, Nos. 4–12), and the mouse H2-
Aa and H2-Ab genes were inserted into pEGFP-N1
(Table 1, Nos. 1 and 2) to enable identification by con-
focal microscopy. These Ii-segment/F306 hybrids were
also inserted into prokaryotic expression vectors pGEX-
4 T-1 (Table 1, Nos. 13–18) for immunization antigen.Additionally, F306 was inserted into pET-32a (No. 17)
for expression of the coating antigen used in the ELISA.
Mouse H2-Ab genes were inserted into PCMV-Myc
(Table 1, No. 3) for the expression of eukaryotic protein
by immunoprecipitation and western blotting. All the
constructed hybrids were identified by sequencing.
Cell culture, transfection and confocal microscopy
COS7 cells were obtained from Biology Science College,
University of Science and Technology of China. The
cells were grown at 37 °C in the presence of 5% CO2 in
Dulbecco’s modified Eagle’s medium with 10% fetal calf
serum (FCS) (GIBCO, USA). Transfection of COS7 cells
was done using Lipofectamine 2000 (Invitrogen) reagent
following the manufacturer’s instructions. Briefly, the hy-
brid vectors and media (amount depending on the size
of the well) were mixed together, and Lipofectamine
2000 (twice the amount of the hybrid vector) was mixed
with the medium in a separate tube. The medium con-
taining the hybrid vectors and the medium containing
Lipofectamine were mixed together, allowed to sit for
15–20 min at room temperature, and added slowly to
the well. After 5 h, the medium was replaced with fresh
media containing penicillin and streptomycin, and 10%
fetal bovine serum. After 24 h, images of the COS7 cells
were acquired with a Zeiss confocal laser scanning
microscope (CLSM) using a × 60 oil objective [excitation
at 488 nm for red fluorescent protein and emission at
515 nm for green fluorescent protein (GFP)].
Immunoprecipitation and western blotting
Immunoprecipitation included cotransfection of the
COS7 cells seeded in 25-cm2 plates with fusion genes
H2-Ab/Myc and Ii/GFP, Ii/F306/GFP, Ii-key/F306/DN/
GFP, Cyt/TM/Ii-key/F306/DN/GFP or Cyt/TM/Ii-key/
F306/GFP, respectively. At 36 h post-transfection, the
cells were harvested and lysed in 1 mL immunoprecipi-
tation lysis buffer (50 mM Tris–HCl, 150 mM NaCl, 1%
Nonidet P40, and 0.5% sodium deoxycholate, 1 Protease
Inhibitor Cocktail Tablets) at 4°C for 1 h. The cells were
then centrifuged at 12 000 g at 4°C for 1 h, and 20 μL
Protein A/G Plus-Agarose beads (GE Healthcare, USA)
were added to the supernatants and incubated at 4°C
for 2 h. After centrifugation at 12 000 g for 20 s at 4°C,
2 μL antibody to Myc (Zhongshan Golden Bridge Bio-
technology, Beijing, China) was added to the superna-
tants and incubated for 2 h at 4 °C. The immune
complexes were isolated using 50 μL Protein A/G Plus-
Agarose beads at 4°C overnight. Centrifugation involved
suspending residue in 1 mL immunoprecipitation lysis
buffer, buffer 2 (50 mM Tris–HCl, 500 mM NaCl, 0.1%
Nonidet P40, 0.05% sodium deoxycholate) and buffer 3
(50 mM Tris–HCl, 0.1% Nonidet P40, 0.05% sodium
deoxycholate) for 20 min and adding Protein A/G Plus-
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ing three times. Subsequently, washed immunoprecipi-
tates were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred onto the polyvinylidene fluoride membrane
(Millipore, Schwalbach, Germany). The blots were
blocked with 10% (v/v) FCS for 1 h and then probed for
1 h with a murine antibody to GFP (Zhongshan Golden
Bridge Biotechnology), followed by washing and incuba-
tion for 2 h with horseradish peroxidase (HRP)-conju-
gated secondary Abs (goat anti-mouse IgG, Zhongshan
Golden Bridge Biotechnology) and an ECL detection sys-
tem (Pierce Roclford).
Expression and purification of antigens
A homologous series of F306 or Ii-segments/F306-epitope
hybrids cloned into pGEX-4 T-1 and pET-32a was trans-
fected into E. coli expression strain Rosetta. Antigen ex-
pression was induced by 1 mmol/L IPTG. All proteins
were extracted in denaturing conditions according to the
Qiagen protocol and purified by immobilized-metal affin-
ity chromatography with Ni-NTA agarose beads following
the manufacturer’s instructions (Amersham Biosciences,
Little Chalfont, UK), and found to be >98% pure by analyt-
ical HPLC. They were dissolved in sterile distilled water
(5 mg/mL) and stored at −70 °C.
Mice and immunization
Balb/c female mice (10 weeks old) were obtained from
the Animal Centre of Anhui Medicine University and
bred under specific pathogen-free conditions at the facil-
ity. All experimental procedures were performed follow-
ing the Anhui Medicine University animal care
guidelines under an approved protocol. Thirty five mice
were divided into seven groups. Mice to be immunized
were anesthetized and injected intraperitoneally with
50 μg of each protein antigen. The animals received the
protein doses at week 0, with complete Freund’s adju-
vant as a 1:1 (v/v) emulsion in 100 μL. The second
immunization occurred at weeks 2 in incomplete
Freund’s adjuvant, and the third immunization took
place at week 3 without adjuvant were carried out. One
control group of mice was injected as above without any
antigen. The sera were prepared at week 4 from blood
collected from mice via the tail vein, and were stored at
−20°C until used for estimation of the antibody titers.
Detection of antibody with ELISA
Ninety-six-well EIA/RIA plates (COSTAR, USA) were
coated with 5 μg/mL His-F306 peptide and then blocked
with 0.05% Tween-20 in PBS (PBST) containing 1% bo-
vine serum albumin. The sera were added to the top row
of each plate, and serial 1:2 dilutions in PBST were then
placed in subsequent rows. The plates were incubatedfor 45 min at room temperature and washed with PBST.
A goat anti-mouse IgG HRP conjugate (Zhongshan
Golden Bridge Biotechnology) diluted 1:5000 was used
as a secondary antibody and incubated for 45 min, fol-
lowed by addition of OPD peroxidase (Sigma, USA) used
as a substrate. After 15 min of incubation at room
temperature, the absorbance was measured at 405 nm.
Statistical analysis
Statistical differences were calculated by one-way ana-
lysis of variance with post-test. Significance was defined
as P < 0.01. All functional assays, e.g., specific antibody
titers in ELISA, were performed in quadruplicate.
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